Crispr therapeutics CEO sells shares worth $413,578

In a recent transaction, Samarth Kulkarni, the Chief Executive Officer of CRISPR Therapeutics AG (NASDAQ:CRSP), sold 10,031 common shares of the company, totaling approximately $413,578. The shares were sold at a price of $41.23 each on March 21, 2025. The transaction occurred as CRISPR’s stock, currently valued at $42.62, shows significant volatility with a beta of 1.76. According to InvestingPro analysis, the company’s current market capitalization stands at $3.66 billion. This transaction was part of a mandatory sale to cover tax obligations related to the vesting of restricted stock units, as per the company’s RSU Settlement Policy.

Additionally, on March 20, 2025, Kulkarni acquired 19,688 common shares through the vesting of restricted stock units. The acquisition did not involve any cash transaction as each restricted stock unit represents a contingent right to receive one share of CRSP common stock.

Following these transactions, Kulkarni now directly owns 195,085 shares of CRISPR Therapeutics. Furthermore, an indirect holding of 85,622 shares is maintained under The Kulkarni 2023 GRAT. The sales and acquisitions reflect the ongoing management of equity compensation and tax obligations by the company’s executive. InvestingPro subscribers can access 8 additional key insights about CRISPR Therapeutics, including detailed analysis of the company’s financial health and growth prospects.

In other recent news, CRISPR Therapeutics has been the focus of several analyst updates and strategic evaluations. Citi analysts adjusted their price target for the company to $82, maintaining a Buy rating, and highlighted the progress of Casgevy with over 50 treatment centers activated globally. Meanwhile, Evercore ISI upgraded CRISPR Therapeutics’ stock rating from In Line to Outperform, raising the price target to $99, driven by optimism about upcoming catalysts and the company’s strong cash position of $1.9 billion. Stifel, on the other hand, reduced their price target to $49 while holding a neutral stance, citing a cautious outlook on Casgevy’s market uptake.

TD Cowen upgraded CRISPR Therapeutics from Sell to Hold, maintaining a price target of $35, noting reduced downside risk for the stock. The firm’s analysts emphasize the importance of management’s actions in accelerating Casgevy’s launch or demonstrating the value of their pipeline. Evercore ISI analysts expressed particular optimism about the potential of in vivo programs CTX320 and CTX310, assigning probabilities of success at 10% and 5%, respectively. Stifel mentioned the stringent safety requirements for in vivo gene editing treatments, which could impact investor sentiment. These developments collectively underscore a period of strategic reassessment and anticipation for CRISPR Therapeutics as it navigates its pipeline and market opportunities.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.